Superworth

Solventum free cash flow SOLV

Cash from operations less capital spending, by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
−$118M
Latest quarter, Q2 FY26
$144M
+144% on a year earlier
Fiscal year 2025
−$10M
−101% on the year before

Solventum's free cash flow was −$118M over the twelve months to Jun 30, 2026, down 180% on a year earlier.

In its latest quarter, Q2 FY26, it was $144M, up 144% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$10M−101%
FY2024$805M−50%
FY2023$1.6Bn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26$144M+144%−$118M
Q1 FY26−$273Mn/a−$203M
Q4 FY25$32M−65%−$10M
Q3 FY25−$21M−128%$50M
Q2 FY25$59M−80%$147M
Q1 FY25−$80M−124%$385M
Q4 FY24$92M−80%$805M
Q3 FY24$76M−82%$1.2B
Q2 FY24$297M+1%$1.5B
Q1 FY24$340M−23%$1.5B
Q4 FY23$459Mn/a$1.6B
Q3 FY23$427Mn/an/a

Against its peers

Companies in Medical - Instruments & Supplies nearest Solventum's size, closest first, today.

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Solventum

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.